文献速递类风湿关节炎

非戈替尼在未用甲氨蝶呤且预后不良因素多的类风湿关节炎患者中的疗效与安全性:FINCH 3事后分析

Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3.
PubMed 文献 · RMD Open · 2021-01-01

该研究为FINCH 3 III期随机双盲活性对照试验的事后分析,评估非戈替尼在未用甲氨蝶呤且具有多个预后不良因素的类风湿关节炎患者中的疗效与安全性。510例(40.8%)患者具有全部四种预后不良因素,非戈替尼200mg联合甲氨蝶呤在该亚组中的疗效与总体人群相当,且安全性无新信号。

要点

  • 非戈替尼200mg联合甲氨蝶呤在具有全部预后不良因素的患者中疗效与总体人群相当。
  • 该联合方案在ACR20/50/70应答、DAS28(CRP)<2.6及缓解率方面优于甲氨蝶呤单药。
  • 非戈替尼100mg联合甲氨蝶呤及200mg单药未一致优于甲氨蝶呤单药。

核心结论

  • 非戈替尼200mg联合甲氨蝶呤在具有多个预后不良因素的患者中疗效和安全性相似于总体人群。

研究设计与样本

  • FINCH 3研究为III期随机双盲活性对照试验(NCT02886728),本分析为事后分析。
  • 患者接受非戈替尼200mg或100mg联合甲氨蝶呤≤20mg/周、非戈替尼200mg单药或甲氨蝶呤单药治疗至52周。
  • 预后不良因素包括类风湿因子或抗环瓜氨酸肽抗体阳性、高敏C反应蛋白≥4mg/L、DAS28(CRP)>5.1及存在骨侵蚀。

主要发现

  • 1249例患者中510例(40.8%)具有全部四种预后不良因素。
  • 在该亚组中,非戈替尼200mg联合甲氨蝶呤的ACR20/50/70应答率、DAS28(CRP)<2.6及缓解率与总体人群相当。
  • 非戈替尼200mg联合甲氨蝶呤较甲氨蝶呤单药在身体功能和疼痛改善及结构损伤抑制方面更优。
  • 非戈替尼100mg联合甲氨蝶呤及非戈替尼200mg单药未一致优于甲氨蝶呤单药。
  • 非戈替尼安全性在预后不良因素患者中与总体人群相当,未观察到新安全信号。

关键数值与推荐

  • 预后不良因素定义:类风湿因子或抗环瓜氨酸肽抗体阳性、高敏C反应蛋白≥4mg/L、DAS28(CRP)>5.1、存在骨侵蚀。
  • 非戈替尼200mg联合甲氨蝶呤组在ACR20/50/70应答、DAS28(CRP)<2.6及缓解率方面高于甲氨蝶呤单药组。

临床怎么用

  • 对于未用甲氨蝶呤且具有多个预后不良因素的类风湿关节炎患者,可考虑非戈替尼200mg联合甲氨蝶呤治疗。
  • 非戈替尼100mg联合甲氨蝶呤或200mg单药在该类患者中未显示一致优于甲氨蝶呤单药。

局限性

  • 本分析为事后分析,亚组比较为非正式比较。
  • 原文未报告具体的效应量、置信区间或P值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This analysis evaluated efficacy and safety of filgotinib, a Janus-associated kinase 1-preferential inhibitor, in methotrexate (MTX)-naive patients with rheumatoid arthritis (RA) with multiple poor prognostic factors (PPFs). METHODS: This was a post hoc analysis of the phase III, randomised, double-blind, active-controlled, FINCH 3 study (clinicaltrials.gov NCT02886728). Patients received once-daily oral filgotinib 200 or 100 mg plus once-weekly oral MTX ≤20 mg (FIL200 + MTX and FIL100 + MTX), filgotinib 200 mg monotherapy (FIL200), or oral MTX monotherapy (MTX-mono) for up to 52 weeks. PPFs investigated were seropositivity for rheumatoid factor or anticyclic citrullinated peptide antibodies, high-sensitivity C reactive protein (CRP) ≥4 mg/L, Disease Activity Score in 28 joints with CRP (DAS28(CRP)) >5.1, and presence of erosions. Filgotinib efficacy and safety in patients with all four PPFs at baseline were explored versus MTX-mono within this subgroup and compared informally with the overall population. RESULTS: Of 1249 patients in FINCH 3, 510 (40.8%) had all PPFs. Efficacy of FIL200 + MTX among these patients was comparable to the overall population, with higher rates of 20%/50%/70% improvement from baseline by American College of Rheumatology criteria, DAS28(CRP) <2.6, and remission; greater improvement in physical function and pain; and better inhibition of structural damage relative to MTX-mono. FIL100 + MTX and FIL200 were not consistently more efficacious versus MTX-mono. Safety of filgotinib in patients with PPFs was comparable to the overall population; no new safety signals were observed. CONCLUSION: FIL200 + MTX efficacy and safety in patients with multiple PPFs were similar to the overall population.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Aletaha D, Westhovens R, Gaujoux-Viala C, et al. Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3. RMD Open. 2021. PMID: 34385364. doi:10.1136/rmdopen-2021-001621

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。